GlioRay is developing nanocarrier-based Auger radioligand therapy technology specifically for glioblastoma treatment, enabling targeted delivery of radiation to cancer cells. This approach minimizes damage to surrounding healthy tissue while enhancing therapeutic efficacy, addressing the critical need for more precise cancer therapies.
Funding
Funding not disclosed
Founders
Product
Problem
Glioblastoma, a highly aggressive brain cancer, presents a significant challenge due to its infiltrative nature and resistance to conventional treatments. Current therapies often lack precision, leading to damage to surrounding healthy brain tissue and limited efficacy in eradicating cancer cells.
Solution
GlioRay is developing a nanocarrier-based Auger radioligand therapy designed for targeted treatment of glioblastoma. This technology utilizes specialized nanocarriers to deliver radiation directly to cancer cells, minimizing exposure to healthy tissue. By precisely targeting the tumor, GlioRay's approach aims to enhance therapeutic efficacy while reducing the harmful side effects associated with traditional radiation therapy. The nanocarriers are engineered to selectively bind to glioblastoma cells, ensuring that the radiation is concentrated at the tumor site. This targeted delivery system has the potential to improve patient outcomes and quality of life by providing a more effective and less toxic treatment option.
Target Audience
The primary target audience includes oncologists, radiation oncologists, and hospitals specializing in the treatment of glioblastoma, as well as patients diagnosed with glioblastoma and their families.
Features
- Nanocarrier-based drug delivery system for targeted radiation therapy.
- Auger radioligand technology for precise cancer cell destruction.
- Selective binding to glioblastoma cells to minimize off-target effects.